June 20 Reuters Eli Lilly and Co agreed to buy Dice Therapeutics Inc for about 2.4 billion in cash on Tuesday, bolstering its immune diseaserelated portfolio with a largely oral drug developer.

Dice39;s lead drug DC806, which is currently in a midstage trial, is an immunology drug for a skin condition called psoriasis and other diseases.

The drug39;s mechanism is similar to Lilly39;s Taltz and works by inhibiting a protein called IL17, which provides inflammatory signal.

However, unlike Taltz, which is an injection, Dice is developing drugs, including its lead candidate, on its proprietary technology platform for oral medicines.

Indianapolisheadquartered Lilly is focusing on immunology to drive future growth, along with a widely expected approval of obesity drug candidate tirzepatide.

The company, which last year saw a sharp drop in sales of its insulin products due to price cuts, last month said it plans to be a top player in immunology and secure approval for at least 11 indications by the end of 2025.

Lilly has offered Dice 48 per share in cash, a premium of about 42 to the stock39;s last close. Shares of Dice were up 37.8 premarket on Tuesday.

Lilly39;s Taltz garnered 2.48 billion in 2022 while its other immunology drug Olumiant generated 830.5 million in sales.

Stifel analyst Alex Thompson does not expect to see any obvious concerns from the U.S. Federal Trade Commission, which has been scrutinizing large pharmaceutical deals recently.

Lilly39;s shares have…